Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
10:30am, Friday, 09'th Aug 2024
NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
06:20pm, Thursday, 08'th Aug 2024
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $2.66 per share a year ago.
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
04:01pm, Thursday, 08'th Aug 2024
– Continued strong revenue performance – – NDAs for sepiapterin and Translarna™ submitted to FDA – – Positive interim data readout from PTC518 PIVOT-HD study – – On track to achieve re
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
03:50pm, Wednesday, 07'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised t
Unlocking Q2 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics
10:20am, Tuesday, 06'th Aug 2024
Get a deeper insight into the potential performance of PTC Therapeutics (PTCT) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
03:41pm, Saturday, 03'rd Aug 2024
NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
06:44pm, Thursday, 01'st Aug 2024
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
09:45am, Wednesday, 31'st Jul 2024
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA
08:00am, Tuesday, 30'th Jul 2024
WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
10:30am, Friday, 26'th Jul 2024
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
04:30pm, Thursday, 25'th Jul 2024
WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2024 financial res
Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
11:07am, Thursday, 25'th Jul 2024
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
08:00pm, Wednesday, 24'th Jul 2024
NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
03:45pm, Tuesday, 23'rd Jul 2024
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
03:53pm, Saturday, 20'th Jul 2024
NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investor
